TDMS Study 92013-06 Pathology Tables
NTP Experiment-Test: 92013-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-METHYLIMIDAZOLE Date: 01/12/04
Route: DOSED FEED Time: 14:34:49
FINAL #1 MICE
Facility: Southern Research Institute
Chemical CAS #: 822-36-6
Lock Date: 09/13/02
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 92013-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-METHYLIMIDAZOLE Date: 01/12/04
Route: DOSED FEED Time: 14:34:49
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 312 PPM 625 PPM 1250 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 3 4 3 3
Natural Death 4 6 4 7
Survivors
Terminal Sacrifice 42 40 41 39
Natural Death 1 2 1
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (48) (50) (50) (49)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Intestine Large, Cecum (49) (48) (46) (46)
Histiocytic Sarcoma 1 (2%)
Intestine Small, Duodenum (48) (47) (49) (48)
Carcinoma 2 (4%)
Histiocytic Sarcoma 1 (2%)
Polyp Adenomatous 1 (2%)
Intestine Small, Jejunum (50) (48) (47) (47)
Intestine Small, Ileum (48) (45) (48) (48)
Liver (50) (50) (50) (50)
Hepatocellular Carcinoma 1 (2%) 2 (4%) 1 (2%)
Hepatocellular Adenoma 4 (8%) 5 (10%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 2 (4%)
Mast Cell Tumor Malignant 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Mesentery (3) (7) (7) (4)
Carcinoma, Metastatic, Mammary Gland 1 (14%)
Histiocytic Sarcoma 1 (14%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (14%)
Pancreas (49) (48) (48) (49)
Sarcoma, Metastatic, Skin 1 (2%)
Salivary Glands (50) (48) (50) (49)
Stomach, Forestomach (50) (50) (50) (50)
Page 2
NTP Experiment-Test: 92013-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-METHYLIMIDAZOLE Date: 01/12/04
Route: DOSED FEED Time: 14:34:49
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 312 PPM 625 PPM 1250 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Squamous Cell Carcinoma 2 (4%)
Squamous Cell Papilloma 2 (4%) 1 (2%) 2 (4%)
Stomach, Glandular (49) (49) (50) (49)
Adenoma 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Capsule, Adenoma 1 (2%)
Adrenal Medulla (50) (50) (50) (50)
Pheochromocytoma Malignant 1 (2%) 1 (2%)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (49) (48) (47) (49)
Adenoma 3 (6%)
Carcinoma 1 (2%) 1 (2%)
Pituitary Gland (49) (46) (49) (50)
Pars Distalis, Adenoma 5 (10%) 4 (9%) 3 (6%) 2 (4%)
Thyroid Gland (50) (49) (50) (48)
Bilateral, Adenoma 1 (2%)
Follicular Cell, Adenoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 92013-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-METHYLIMIDAZOLE Date: 01/12/04
Route: DOSED FEED Time: 14:34:49
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 312 PPM 625 PPM 1250 PPM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (48) (49) (49) (50)
Cystadenoma 2 (4%) 1 (2%) 1 (2%)
Granulosa Cell Tumor Benign 2 (4%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Luteoma 1 (2%) 2 (4%) 2 (4%)
Tubulostromal Adenoma 1 (2%) 1 (2%)
Uterus (50) (50) (50) (50)
Carcinoma 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 2 (4%) 2 (4%)
Leiomyoma 1 (2%)
Polyp Stromal 2 (4%) 2 (4%)
Sarcoma, Metastatic, Skin 1 (2%)
Sarcoma Stromal 1 (2%)
Schwannoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Hemangiosarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
Lymph Node (3) (9) (12) (7)
Iliac, Histiocytic Sarcoma 1 (11%)
Mediastinal, Histiocytic Sarcoma 1 (14%)
Pancreatic, Squamous Cell Carcinoma,
Metastatic, Stomach, Forestomach 1 (8%)
Lymph Node, Mandibular (47) (47) (48) (48)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mesenteric (49) (47) (49) (50)
Histiocytic Sarcoma 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Spleen (49) (49) (49) (49)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hemangiosarcoma 2 (4%) 2 (4%)
Histiocytic Sarcoma 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
Thymus (49) (49) (50) (48)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 92013-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-METHYLIMIDAZOLE Date: 01/12/04
Route: DOSED FEED Time: 14:34:49
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 312 PPM 625 PPM 1250 PPM
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (50) (49) (49)
Adenoma 1 (2%)
Carcinoma 1 (2%) 1 (2%) 1 (2%)
Skin (50) (50) (50) (50)
Basal Cell Carcinoma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 2 (4%) 1 (2%)
Subcutaneous Tissue, Melanoma Benign 1 (2%)
Subcutaneous Tissue, Sarcoma, Poorly
Differentiated 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Osteosarcoma 1 (2%)
Skeletal Muscle (1) (1) (2) (2)
Sarcoma, Metastatic, Skin 1 (100%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 2 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Histiocytic Sarcoma 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
Spinal Cord (2) (1)
Osteosarcoma, Metastatic, Bone 1 (100%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 8 (16%) 12 (24%) 6 (12%)
Alveolar/Bronchiolar Adenoma, Multiple 4 (8%) 2 (4%)
Alveolar/Bronchiolar Carcinoma 3 (6%) 2 (4%) 6 (12%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Histiocytic Sarcoma 2 (4%)
Page 5
NTP Experiment-Test: 92013-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-METHYLIMIDAZOLE Date: 01/12/04
Route: DOSED FEED Time: 14:34:49
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 312 PPM 625 PPM 1250 PPM
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Mast Cell Tumor Malignant 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Nose (50) (49) (50) (50)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (50) (50) (50) (50)
Adenoma 6 (12%) 1 (2%) 5 (10%) 6 (12%)
Carcinoma 1 (2%) 1 (2%) 2 (4%)
Zymbal's Gland (1) (1)
Carcinoma 1 (100%) 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (50) (50) (50)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Histiocytic Sarcoma 1 (2%)
Urinary Bladder (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%) 1 (2%) 3 (6%) 2 (4%)
Lymphoma Malignant 7 (14%) 10 (20%) 12 (24%) 13 (26%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 92013-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-METHYLIMIDAZOLE Date: 01/12/04
Route: DOSED FEED Time: 14:34:49
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 312 PPM 625 PPM 1250 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 29 36 37 40
Total Primary Neoplasms 46 50 55 66
Total Animals with Benign Neoplasms 18 23 23 21
Total Benign Neoplasms 23 28 30 28
Total Animals with Malignant Neoplasms 20 20 23 29
Total Malignant Neoplasms 23 22 25 38
Total Animals with Metastatic Neoplasms 2 1 2 1
Total Metastatic Neoplasm 9 6 7 2
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 92013-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-METHYLIMIDAZOLE Date: 01/12/04
Route: DOSED FEED Time: 14:34:49
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 312 PPM 625 PPM 1250 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Natural Death 4 6 8
Moribund Sacrifice 1 3
Survivors
Natural Death 1
Terminal Sacrifice 44 44 42 46
Other 1
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Small, Duodenum (50) (49) (48) (50)
Carcinoma 2 (4%)
Polyp Adenomatous 1 (2%)
Intestine Small, Jejunum (48) (47) (48) (50)
Carcinoma 1 (2%)
Intestine Small, Ileum (49) (46) (48) (49)
Liver (50) (50) (50) (50)
Hemangiosarcoma 1 (2%) 1 (2%)
Hemangiosarcoma, Multiple 1 (2%)
Hepatocellular Carcinoma 8 (16%) 11 (22%) 10 (20%) 7 (14%)
Hepatocellular Carcinoma, Multiple 2 (4%) 2 (4%) 1 (2%) 3 (6%)
Hepatocellular Adenoma 14 (28%) 7 (14%) 10 (20%) 11 (22%)
Hepatocellular Adenoma, Multiple 3 (6%) 2 (4%) 1 (2%)
Mesentery (4) (7) (2) (3)
Hemangiosarcoma 1 (14%) 1 (33%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (14%)
Sarcoma, Poorly Differentiated 1 (14%)
Oral Mucosa (1)
Squamous Cell Carcinoma 1 (100%)
Pancreas (49) (49) (50) (50)
Sarcoma, Metastatic, Mesentery 1 (2%)
Salivary Glands (50) (50) (50) (50)
Stomach, Forestomach (49) (50) (50) (50)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 2 (4%) 3 (6%)
Stomach, Glandular (49) (50) (49) (50)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Page 8
NTP Experiment-Test: 92013-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-METHYLIMIDAZOLE Date: 01/12/04
Route: DOSED FEED Time: 14:34:49
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 312 PPM 625 PPM 1250 PPM
____________________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50)
Adenoma 1 (2%)
Capsule, Adenoma 3 (6%) 1 (2%) 1 (2%)
Capsule, Carcinoma 1 (2%)
Islets, Pancreatic (49) (49) (50) (50)
Adenoma 1 (2%) 1 (2%)
Pituitary Gland (49) (48) (49) (50)
Pars Distalis, Adenoma 1 (2%)
Thyroid Gland (50) (50) (50) (50)
Follicular Cell, Adenoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1)
Schwannoma Malignant 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Prostate (50) (50) (50) (50)
Carcinoma 1 (2%)
Testes (50) (50) (50) (50)
Hemangiosarcoma 1 (2%) 1 (2%)
Interstitial Cell, Adenoma 2 (4%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Hemangiosarcoma 1 (2%) 1 (2%)
Lymph Node (2) (2) (1) (2)
Lymph Node, Mandibular (48) (50) (48) (45)
Lymph Node, Mesenteric (49) (48) (48) (50)
Page 9
NTP Experiment-Test: 92013-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-METHYLIMIDAZOLE Date: 01/12/04
Route: DOSED FEED Time: 14:34:49
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 312 PPM 625 PPM 1250 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Spleen (49) (49) (50) (50)
Hemangiosarcoma 1 (2%) 1 (2%)
Thymus (48) (49) (45) (45)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (49)
Squamous Cell Carcinoma 1 (2%)
Sebaceous Gland, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1) (2) (1) (1)
Carcinoma, Metastatic, Prostate 1 (100%)
Hemangiosarcoma 1 (100%)
Sarcoma, Metastatic, Mesentery 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 6 (12%) 10 (20%) 10 (20%) 14 (28%)
Alveolar/Bronchiolar Adenoma, Multiple 2 (4%) 1 (2%) 3 (6%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 3 (6%) 4 (8%) 7 (14%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%) 1 (2%)
Carcinoma, Metastatic, Prostate 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 3 (6%) 3 (6%) 3 (6%) 3 (6%)
Schwannoma Malignant, Metastatic, Tissue NOS 1 (2%)
Mediastinum, Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 92013-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-METHYLIMIDAZOLE Date: 01/12/04
Route: DOSED FEED Time: 14:34:49
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 312 PPM 625 PPM 1250 PPM
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (50) (50) (50) (50)
Adenoma 3 (6%) 8 (16%) 4 (8%) 6 (12%)
Adenoma, Multiple 1 (2%) 1 (2%)
Carcinoma 1 (2%) 1 (2%)
Bilateral, Adenoma 1 (2%)
Bilateral, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Renal Tubule, Adenoma 2 (4%)
Renal Tubule, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Lymphoma Malignant 3 (6%) 3 (6%) 4 (8%) 2 (4%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 11
NTP Experiment-Test: 92013-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-METHYLIMIDAZOLE Date: 01/12/04
Route: DOSED FEED Time: 14:34:49
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 312 PPM 625 PPM 1250 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 34 38 36 39
Total Primary Neoplasms 55 68 57 63
Total Animals with Benign Neoplasms 26 29 23 27
Total Benign Neoplasms 34 38 31 38
Total Animals with Malignant Neoplasms 15 25 21 22
Total Malignant Neoplasms 21 30 26 25
Total Animals with Metastatic Neoplasms 4 3 4 3
Total Metastatic Neoplasm 5 6 6 3
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------